Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25637647 | 0.88 | SIRT6 (0.39) | PLK1CSNK2A1PLK3MEN1KMT2A | |
| SCHEMBL25637690 | 0.81 | SIRT6 (0.36) | PLK1CSNK2A1PLK3MEN1KMT2A | |
| SCHEMBL25056315 | 0.81 | PLK1 (0.33) | PLK1CSNK2A1PLK3MKNK1MKNK2 | |
| SCHEMBL25637666 | 0.80 | TDP1 (0.40) | PLK1CSNK2A1PLK3MEN1KMT2A | |
| SCHEMBL25637694 | 0.77 | ALDH1A1 (0.38) | PLK1CSNK2A1PLK3MEN1KMT2A | |
| SCHEMBL25639760 | 0.76 | SIRT6 (0.38) | MEN1KMT2A | |
| SCHEMBL25637830 | 0.75 | TDP1 (0.36) | MEN1KMT2A | |
| SCHEMBL25637849 | 0.75 | SIRT6 (0.38) | MEN1KMT2A | |
| SCHEMBL25056359 | 0.75 | PKM (0.38) | PLK1CSNK2A1PLK3MEN1KMT2A | |
| SCHEMBL25637702 | 0.75 | CYP11B1 (0.36) | PLK1CSNK2A1PLK3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | PDK1 1351/4885PLK1 76/4885CSNK2A1 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.